Orlistat Teva

Orlistat, the active ingredient in Orlistat Teva, is a lipase inhibitor presented as an oral tablet for oral use. It works by reducing the absorption of dietary fat and is indicated to support weight loss in overweight and obese adults when used together with a reduced‑calorie, low‑fat diet and lifestyle changes. The medication is intended for individuals with a body mass index of 30 kg/m² or higher, or 27 kg/m² with associated risk factors.

GNH USA supplies Orlistat Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Orlistat is indicated for conditions related to excess body weight and works as part of a comprehensive weight‑management program.

Obesity: assists in achieving clinically significant weight loss when combined with a calorie‑restricted, low‑fat diet. Overweight with risk factors: helps reduce body weight and improve associated metabolic parameters. Weight management in adults: supports long‑term weight control as an adjunct to diet and exercise. Metabolic syndrome: contributes to weight reduction which may improve insulin sensitivity.

Orlistat may cause gastrointestinal and other adverse reactions, which are categorized by frequency.

Common Side Effects: - Oily spotting on undergarments after meals. - Increased flatulence with oily discharge. - Abdominal cramping or pain. - Fecal urgency or incontinence. - Increased number of bowel movements. - Oily or greasy stools.

Serious or Rare Side Effects: - Severe allergic reactions such as anaphylaxis. - Acute liver injury, including hepatitis. - Pancreatitis. - Fat‑soluble vitamin deficiencies with prolonged use. - Rare cases of kidney stones.

Before initiating therapy, several safety considerations should be reviewed.

Assess BMI: confirm the patient meets the BMI criteria for treatment. Monitor vitamin levels: supplement vitamins A, D, E and K as needed due to reduced fat absorption. Limit dietary fat: advise patients to keep fat intake below 30% of total calories. Contraindicated in chronic malabsorption syndromes: avoid use in patients with such conditions. Pregnancy and lactation: only use if the potential benefit outweighs the risk. Store at ambient temperature: keep below 25°C, retain in the original packaging and protect from moisture.

Orlistat can affect the absorption of several concomitant medications.

Major Interactions (Avoid): - Cyclosporine: reduced systemic exposure may compromise immunosuppression. - Levothyroxine: decreased absorption can lead to sub‑therapeutic thyroid levels. - Warfarin: altered vitamin K absorption may increase INR and bleeding risk.

Moderate Interactions (Monitor Closely): - Oral contraceptives: efficacy may be reduced; advise backup contraception. - Fat‑soluble vitamin supplements: absorption may be impaired, consider timing. - Antidiabetic agents: monitor glucose as weight loss can affect glycemic control.